Related Experiment Video

Updated: Jun 14, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

RHCG inhibition promotes the sensitivity of PIK3CA-mutant non-small lung cancer to PI3K inhibitor

Haitao Liu1, Muqun Wang1, Yingying Pang2

  • 1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, PR China.

Histology and Histopathology
|June 13, 2025
PubMed

Insights

Researchers identified RHCG as a potential therapeutic target in PIK3CA-mutated non-small cell lung cancer (NSCLC). Targeting RHCG may enhance the effectiveness of PI3K inhibitors, offering a new treatment strategy for NSCLC patients with these specific mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • PIK3CA mutations are prevalent in non-small cell lung cancer (NSCLC), but targeted therapies are lacking.
  • PI3K inhibitors are approved for other hematologic malignancies but not yet for lung cancer.

Purpose of the Study:

  • To identify novel therapeutic targets in PIK3CA-mutated NSCLC.
  • To investigate the role of RHCG in NSCLC and its potential as a drug target.

Main Methods:

  • Analysis of The Cancer Genome Atlas (TCGA) database.
  • RHCG gene expression analysis in NSCLC.
  • RHCG knockdown experiments in cancer cell lines.
  • Assessment of cell proliferation, apoptosis, and downstream signaling pathways (AKT, S6RP).

Main Results:

  • RHCG is highly expressed in PIK3CA-mutated NSCLC and correlates with poor prognosis.
  • RHCG knockdown inhibits proliferation and induces apoptosis in PIK3CA-mutated NSCLC cells.
  • RHCG knockdown sensitizes NSCLC cells to PI3K inhibitors.
  • RHCG knockdown synergizes with PI3K inhibitors to enhance inhibition of AKT and S6RP phosphorylation.

Conclusions:

  • RHCG is a promising therapeutic target for PIK3CA-mutated NSCLC.
  • Targeting RHCG in combination with PI3K inhibitors may represent a novel treatment strategy for NSCLC.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K